Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.

Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ.

Eur J Hum Genet. 2019 Nov 19. doi: 10.1038/s41431-019-0540-0. [Epub ahead of print]

PMID:
31745289
2.

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.

Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM.

N Engl J Med. 2019 Oct 24;381(17):1621-1631. doi: 10.1056/NEJMoa1907096. Epub 2019 Sep 3.

PMID:
31479209
3.

Use of Pharmacogenetic Drugs by the Dutch Population.

Alshabeeb MA, Deneer VHM, Khan A, Asselbergs FW.

Front Genet. 2019 Jul 2;10:567. doi: 10.3389/fgene.2019.00567. eCollection 2019.

4.

Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study.

Janssen PWA, Bergmeijer TO, Vos GA, Kelder JC, Qaderdan K, Godschalk TC, Breet NJ, Deneer VHM, Hackeng CM, Ten Berg JM.

Eur J Clin Pharmacol. 2019 Sep;75(9):1201-1210. doi: 10.1007/s00228-019-02696-z. Epub 2019 Jun 14.

PMID:
31197411
5.

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.

van Rongen A, van der Aa MP, Matic M, van Schaik RHN, Deneer VHM, van der Vorst MM, Knibbe CAJ.

Paediatr Drugs. 2018 Aug;20(4):365-374. doi: 10.1007/s40272-018-0293-1.

6.

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.

Bergmeijer TO, Vos GJ, Claassens DM, Janssen PW, Harms R, der Heide RV, Asselbergs FW, Ten Berg JM, Deneer VH.

Pharmacogenomics. 2018 May;19(7):621-628. doi: 10.2217/pgs-2018-0013. Epub 2018 Apr 27.

7.

Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis.

Schimmelpennink MC, Vorselaars ADM, van Beek FT, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M.

Respir Med. 2018 May;138S:S7-S13. doi: 10.1016/j.rmed.2018.02.009. Epub 2018 Feb 19.

PMID:
29496351
8.

Pharmacogenetic Information in Clinical Guidelines: The European Perspective.

Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP).

Clin Pharmacol Ther. 2018 May;103(5):795-801. doi: 10.1002/cpt.1049. Epub 2018 Mar 30. Review.

PMID:
29460273
9.

Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience.

Bergmeijer TO, Janssen PWA, van Oevelen M, van Rooijen D, Godschalk TC, Kelder JC, Deneer VHM, Serebruany VL, Ten Berg JM.

Cardiology. 2017;138(3):164-168. doi: 10.1159/000475705. Epub 2017 Jul 12.

PMID:
28697492
10.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
11.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Erratum in: Clin Pharmacol Ther. 2017 Jul;102(1):152.

PMID:
28027596
12.

Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period.

Yasmina A, de Boer A, Deneer VH, Souverein PC, Klungel OH.

Br J Clin Pharmacol. 2017 Mar;83(3):632-641. doi: 10.1111/bcp.13139. Epub 2016 Oct 24.

13.

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.

Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, Deneer VH, Grutters JC.

Respir Med. 2016 Jun;115:72-7. doi: 10.1016/j.rmed.2016.04.011. Epub 2016 Apr 23.

14.

Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation.

Nijenhuis VJ, Bennaghmouch N, Hassell M, Baan J Jr, van Kuijk JP, Agostoni P, van 't Hof A, Kievit PC, Veenstra L, van der Harst P, van den Heuvel AF, den Heijer P, Kelder JC, Deneer VH, van der Kley F, Onorati F, Collet JP, Maisano F, Latib A, Huber K, Stella PR, Ten Berg JM.

Am Heart J. 2016 Mar;173:77-85. doi: 10.1016/j.ahj.2015.11.008. Epub 2015 Dec 1.

PMID:
26920599
15.

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.

Qaderdan K, Ishak M, Heestermans AA, de Vrey E, Jukema JW, Voskuil M, de Boer MJ, van't Hof AW, Groenemeijer BE, Vos GJ, Janssen PW, Bergmeijer TO, Kelder JC, Deneer VH, ten Berg JM.

Am Heart J. 2015 Nov;170(5):981-985.e1. doi: 10.1016/j.ahj.2015.07.030. Epub 2015 Aug 4.

PMID:
26542508
16.

Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis?

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2015;7(6):601. doi: 10.2217/imt.15.25. Epub 2015 Jun 22. No abstract available.

17.

Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.

Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, van Moorsel CH, Grutters JC.

Eur Respir J. 2015 Jul;46(1):175-85. doi: 10.1183/09031936.00227014. Epub 2015 Apr 30.

18.

[A potentially fatal intoxication with colchicine].

Boonstra JJ, Kan AA, de Vries I, Deneer VH, Meinders AJ.

Ned Tijdschr Geneeskd. 2015;159:A8144. Dutch.

PMID:
25804106
19.

Anti-TNF therapeutics for the treatment of sarcoidosis.

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2014;6(10):1127-43. doi: 10.2217/imt.14.65. Review.

PMID:
25428650
20.

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.

Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van 't Hof AW, Dewilde WJ, Spanó F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM.

Am Heart J. 2014 Jul;168(1):16-22.e1. doi: 10.1016/j.ahj.2014.03.006. Epub 2014 Mar 21.

PMID:
24952855
21.

Pharmacogenomics of oral antiplatelet drugs.

Yasmina A, de Boer A, Klungel OH, Deneer VH.

Pharmacogenomics. 2014 Mar;15(4):509-28. doi: 10.2217/pgs.14.16. Review.

PMID:
24624918
22.

Application of routine electronic health record databases for pharmacogenetic research.

Yasmina A, Deneer VH, Maitland-van der Zee AH, van Staa TP, de Boer A, Klungel OH.

J Intern Med. 2014 Jun;275(6):590-604. doi: 10.1111/joim.12226. Review.

23.

Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia.

Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn GP, Rijkers GT, Bos WJ, van de Garde EM.

Br J Clin Pharmacol. 2014 Jul;78(1):78-83. doi: 10.1111/bcp.12295.

24.

Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.

Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CA.

J Antimicrob Chemother. 2014 Mar;69(3):715-23. doi: 10.1093/jac/dkt444. Epub 2013 Nov 8.

PMID:
24214905
25.

Current therapy in sarcoidosis, the role of existing drugs and future medicine.

Vorselaars AD, van Moorsel CH, Deneer VH, Grutters JC.

Inflamm Allergy Drug Targets. 2013 Dec;12(6):369-77. Review.

PMID:
24151828
26.

Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.

Deneer VH, van Schaik RH.

Methods Mol Biol. 2013;1015:345-54. doi: 10.1007/978-1-62703-435-7_23.

PMID:
23824868
27.

Methotrexate vs azathioprine in second-line therapy of sarcoidosis.

Vorselaars ADM, Wuyts WA, Vorselaars VMM, Zanen P, Deneer VHM, Veltkamp M, Thomeer M, van Moorsel CHM, Grutters JC.

Chest. 2013 Sep;144(3):805-812. doi: 10.1378/chest.12-1728.

PMID:
23538719
28.

High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial.

Van Der Heyden J, Van Werkum J, Hackeng CM, Kelder JC, Breet NJ, Deneer VH, Ackerstaff RG, Tromp SC, De Vries JP, Vos JA, Suttorp MJ, Elsenberg EH, Van Neerven D, Schonewille WJ, Wolters F, Ten Berg JM.

J Cardiovasc Surg (Torino). 2013 Jun;54(3):337-47. Epub 2012 Nov 8.

PMID:
23138609
29.

Discontinuation of anticoagulant care during admission to a psychiatric hospital.

Abdullah-Koolmees H, Gerbranda T, Deneer VH, Tjoeng MM, De Ridder AJ, Gardarsdottir H, Heerdink ER.

Eur J Clin Pharmacol. 2013 Apr;69(4):1025-9. doi: 10.1007/s00228-012-1398-z. Epub 2012 Oct 23.

PMID:
23090698
30.

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S.

Lancet. 2012 Aug 11;380(9841):572-80. doi: 10.1016/S0140-6736(12)60312-2. Epub 2012 May 17. Erratum in: Lancet. 2012 Aug 11;380(9841):564.

31.

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

ten Berg JM, Deneer VH.

Nat Rev Cardiol. 2012 Mar 13;9(4):192-4. doi: 10.1038/nrcardio.2012.29. No abstract available.

PMID:
22411289
32.

The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.

Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, Breet NJ, Ten Berg JM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2012 Mar;22(3):169-75. doi: 10.1097/FPC.0b013e32834ff6e3.

PMID:
22228204
33.

Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

van Kralingen S, Diepstraten J, Peeters MY, Deneer VH, van Ramshorst B, Wiezer RJ, van Dongen EP, Danhof M, Knibbe CA.

Clin Pharmacokinet. 2011 Nov 1;50(11):739-50. doi: 10.2165/11592890-000000000-00000.

PMID:
21973271
34.

Maintenance of anesthesia in morbidly obese patients using propofol with continuous BIS-monitoring: a comparison of propofol-remifentanil and propofol-epidural anesthesia.

van Kralingen S, van de Garde EM, van Dongen EP, Diepstraten J, Deneer VH, van Ramshorst B, Knibbe CA.

Acta Anaesthesiol Belg. 2011;62(2):73-82.

PMID:
21919373
35.

Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.

Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM, Klungel OH, de Boer A, Deneer VH.

J Thromb Haemost. 2011 Oct;9(10):1892-901. doi: 10.1111/j.1538-7836.2011.04483.x.

36.

Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Deneer VH, van Hemel NM.

Drugs Aging. 2011 Aug 1;28(8):617-33. doi: 10.2165/11591680-000000000-00000. Review.

PMID:
21812498
37.

[Interaction between clopidogrel and proton pump inhibitors].

Harmsze AM, de Boer A, Boot H, Deneer VH, Heringa M, Mol PG, Schalekamp T, Verduijn MM, Verheugt FW, le Comte M.

Ned Tijdschr Geneeskd. 2011;155(28):A2442. Review. Dutch.

PMID:
21771377
38.

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM.

Heart. 2011 Aug;97(15):1239-44. doi: 10.1136/hrt.2010.220509. Epub 2011 May 31.

PMID:
21628721
39.

Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.

van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA.

Eur J Clin Pharmacol. 2011 Oct;67(10):985-92. doi: 10.1007/s00228-011-1048-x. Epub 2011 Apr 16.

PMID:
21499760
40.

Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite.

Harmsze AM, van Werkum JW, Taubert D, Hackeng CM, Deneer VH.

Ann Pharmacother. 2011 Apr;45(4):542-3. doi: 10.1345/aph.1P425. Epub 2011 Apr 12. No abstract available.

PMID:
21487078
41.

Pharmacogenetics: from bench to byte--an update of guidelines.

Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ.

Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16. Review.

PMID:
21412232
42.

CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.

Peters BJ, Harmsze AM, ten Berg JM, Maitland-van der Zee AH, Tjoeng MM, de Boer A, Deneer VH.

Pharmacogenomics. 2011 Feb;12(2):141-4. doi: 10.2217/pgs.10.211. No abstract available.

PMID:
21332306
43.

Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients.

Harmsze AM, Van Werkum JW, Moral F, Ten Berg JN, Hackeng CM, Klungel OH, De Boer A, Deneer VH.

Platelets. 2011;22(2):98-102. doi: 10.3109/09537104.2010.530359. Epub 2010 Dec 8.

PMID:
21142408
44.

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.

Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ, Hackeng CM, Klungel OH, de Boer A, Deneer VH.

Eur Heart J. 2010 Dec;31(24):3046-53. doi: 10.1093/eurheartj/ehq321. Epub 2010 Sep 10.

PMID:
20833683
45.

[Genetic variations affect drug safety and efficacy].

Harmsze AM, Deneer VH, Maitland-van der Zee AH, de Boer A, Klungel OH.

Ned Tijdschr Geneeskd. 2010;154:A1503. Review. Dutch.

PMID:
20699026
46.

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH.

Thromb Haemost. 2010 May;103(5):920-5. doi: 10.1160/TH09-08-0516. Epub 2010 Mar 29.

PMID:
20352154
47.

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM.

JAMA. 2010 Feb 24;303(8):754-62. doi: 10.1001/jama.2010.181. Erratum in: JAMA. 2010 Apr 7;303(13):1257. JAMA. 2011 Jun 1;305(21):2174. JAMA. 2011 Jun 1;305(21):2172-3.

PMID:
20179285
48.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
49.

Genetically determined differences in sodium current characteristics modulate conduction disease severity in mice with cardiac sodium channelopathy.

Remme CA, Scicluna BP, Verkerk AO, Amin AS, van Brunschot S, Beekman L, Deneer VH, Chevalier C, Oyama F, Miyazaki H, Nukina N, Wilders R, Escande D, Houlgatte R, Wilde AA, Tan HL, Veldkamp MW, de Bakker JM, Bezzina CR.

Circ Res. 2009 Jun 5;104(11):1283-92. doi: 10.1161/CIRCRESAHA.109.194423. Epub 2009 Apr 30.

PMID:
19407241
50.

Effect of oxybutynin on exercise-induced sweating in healthy individuals.

van Houte M, Harmsze AM, Deneer VH, Tupker RA.

J Dermatolog Treat. 2008;19(2):101-4. doi: 10.1080/09546630701418754.

PMID:
18484428

Supplemental Content

Loading ...
Support Center